Pharmacyte Biotech Inc Stock Price, News & Analysis

PharmaCyte Biotech (NASDAQ: PMCB) announced positive results from its second FDA-required biocompatibility test of the CypCaps™ product, revealing that the capsule material is non-hemolytic. This test confirms earlier findings that the biocompatibility of the capsule does not cause blood cell destruction. Conducted by a third-party organization, the results align with PharmaCyte’s goal of developing cellular therapies for pancreatic cancer and diabetes using its Cell-in-a-Box® technology, enhancing prospects for clinical advancement.

PharmaCyte Biotech (NASDAQ: PMCB) announced the initial results of biocompatibility studies for its CypCaps product, a component in its pancreatic cancer treatment. The study confirmed that the cellulose sulphate capsules do not activate the complement system, a key part of the human immune response, ensuring safety for patients. Conducted by a third-party GLP lab, this study is part of ongoing research to evaluate the CypCaps' effectiveness and compatibility. Further results from additional studies are expected in the coming weeks.

PharmaCyte Biotech (NASDAQ: PMCB) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. CEO Kenneth L. Waggoner will present and engage in meetings with institutional investors. He emphasized the company's milestone of having sufficient capital for ongoing development of its cancer and diabetes cellular therapies, which utilize the proprietary Cell-in-a-Box® technology. The presentation will be available on-demand from September 13, 2021, at 7:00 a.m. EDT.

PharmaCyte Biotech (NASDAQ: PMCB) announced that its clinical trial product, CypCaps™, remains stable and active 18 months post-storage at -80ºC, affirming a minimum shelf life of 18 months. This positive stability data will contribute to PharmaCyte's updated submission to the FDA aimed at lifting the clinical hold on its Investigational New Drug application (IND) for the treatment of inoperable pancreatic cancer. The ongoing study confirms product integrity and viability, supporting the company’s goal to advance to a Phase 2b clinical trial.

PharmaCyte Biotech (NASDAQ: PMCB) has announced an expansion of its product pipeline to include diabetes and malignant ascites programs, following the successful closing of two public offerings that raised approximately $90 million. CEO Kenneth L. Waggoner emphasized that this funding enables the company to lift the clinical hold imposed by the FDA and proceed with a clinical trial for locally advanced, inoperable pancreatic cancer (LAPC). The additional capital allows PharmaCyte to broaden its development efforts, having previously focused solely on LAPC.

PharmaCyte Biotech (NASDAQ: PMCB) has entered into definitive agreements for a registered direct offering of 14 million shares at $5.00 per share, raising gross proceeds of $70 million. The offering includes unregistered warrants to purchase 7 million additional shares. The funds will be used to address the FDA's clinical hold and conduct a Phase 2b trial for pancreatic cancer. The offering is expected to close around August 23, 2021, pending customary conditions, with H.C. Wainwright & Co. as the placement agent.

PharmaCyte Biotech (NASDAQ: PMCB) announced its successful listing on Nasdaq, marking a significant milestone aimed at enhancing shareholder value. CEO Kenneth L. Waggoner highlighted the benefits of the move, including improved liquidity, expanded shareholder base, and access to capital for advancing their cellular therapies targeting pancreatic cancer and diabetes. A recent $15 million public offering, facilitated by their reverse stock split, will support efforts to address FDA clinical hold requests and launch clinical trials. The company emphasizes increased visibility and opportunities through the Nasdaq platform.

PharmaCyte Biotech (NASDAQ: PMCB) has successfully closed a public offering, raising approximately $15 million. The offering included 3,529,412 shares of common stock and warrants for the same number of shares, with net proceeds of about $13.6 million after deductions. The underwriter, H.C. Wainwright, received an option for an additional 529,411 shares and has partially exercised it. PharmaCyte focuses on developing therapies for cancer and diabetes using its Cell-in-a-Box technology.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has announced the commencement of trading on The Nasdaq Capital Market starting August 10, 2021. The company priced an underwritten public offering of 3,529,412 shares at $4.25 each, yielding approximately $15 million in gross proceeds before expenses. This offering includes warrants exercisable for additional shares and a 30-day option for underwriters to purchase more shares. The offering aims to support PharmaCyte's development of innovative therapies for cancer and diabetes using its Cell-in-a-Box^® technology.